Study of LCB02A for advanced solid tumors with Claudin 18.2
Part of Cancer clinical trials.
This trial tests a new drug called LCB02A, which targets a protein called Claudin 18.2 found on some cancer cells. It is for people with advanced solid tumors that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be advanced and have not responded to standard treatments.
- Your tumor must test positive for the Claudin 18.2 protein.
- You must have at least one tumor that can be measured on scans.
- You must be willing to provide a tumor sample from a previous biopsy or have a new one taken.
- You should be able to take care of yourself (ECOG score 0 or 1).
- Your blood counts and organ function must be within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the safety and side effects of SHR-A1904, and whether it can help people with advanced stomach or pancreatic cancer. To join, your tumor must have high “Claudin 18.2” protein, and you must meet several health and timing requirements.
This trial tests a new drug called ARC101 for people with advanced solid tumors that are Claudin-6 positive. It aims to see if the drug is safe and can help shrink tumors or slow their growth.
This trial tests a combination of two new study drugs (QLS31905 and QL1706) plus chemotherapy against advanced solid tumors that have a specific protein called Claudin18.2. It's for people who have not had any prior treatment for their advanced cancer.
This Phase 1/2 study tests RC118, a cancer medicine, in people with advanced or spread solid tumors that cannot be removed by surgery. It focuses on tumors that show a specific marker called Claudin 18.2, which may help the treatment work better for some patients.
This early-stage trial tests a new radioactive drug (177Lu-DOTA-SNA040) designed to target a protein called Claudin18.2 found on certain cancer cells. The drug delivers radiation directly to tumors in patients with advanced gastric, pancreatic, or bile duct cancers that have stopped responding to standard treatments.
This clinical trial tests a combination of two new drugs, FG-M108 and FG-B901, for people with advanced solid tumors that have a specific protein marker (CLDN18.2). The goal is to see if the combination is safe and effective when standard treatments have failed.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.